Published in J Clin Oncol on May 01, 1997
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer (2001) 1.28
Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res (2009) 1.26
Obesity is an independent predictor of poor survival in metastatic breast cancer: retrospective analysis of a patient cohort whose treatment included high-dose chemotherapy and autologous stem cell support. Int J Breast Cancer (2011) 0.84
Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Br J Cancer (2002) 0.82
Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer. Br J Cancer (2000) 0.80
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study. Br J Cancer (2001) 0.78
Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. Br J Cancer (2003) 0.78
Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer. J Cancer Res Clin Oncol (2003) 0.77
Stem-cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol (2004) 0.77
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. Br J Cancer (1999) 0.76
Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. Br J Cancer (2000) 0.76
Giving medicine a fair trial. Patients' preferences should be assessed. BMJ (2000) 0.75
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol (1998) 0.75
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer. Biol Blood Marrow Transplant (2012) 0.75
Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. J Cancer (2017) 0.75
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (1985) 8.32
The uncertainty principle and industry-sponsored research. Lancet (2000) 7.75
New Giemsa method for the differential staining of sister chromatids. Nature (1974) 7.38
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med (1999) 5.82
Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med (2001) 5.14
Solid cancers after bone marrow transplantation. N Engl J Med (1997) 4.62
IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol (1997) 4.52
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med (2000) 4.50
Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J Clin Microbiol (1982) 4.35
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther (2007) 4.33
Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol (2000) 3.94
Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res (1998) 3.71
Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell (1986) 3.59
Bone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med (1989) 3.46
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Cord-blood-cell transplantation--a real sleeper? N Engl J Med (1995) 3.29
Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med (1994) 3.26
Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant (2002) 3.24
Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol (1998) 3.21
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 3.19
Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant (2007) 3.18
Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood (1994) 2.93
Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med (1993) 2.90
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy. Arch Intern Med (1983) 2.53
HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med (1996) 2.52
Adaptive response of human lymphocytes to low concentrations of radioactive thymidine. Science (1984) 2.46
Protective defunctioning stoma in low anterior resection for rectal carcinoma. Br J Surg (2005) 2.42
The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol (1999) 2.40
Mantle cell lymphoma-- an entity comes of age. Blood (1996) 2.30
Clinical uses of intravenous immunoglobulins. Ann Intern Med (1990) 2.29
Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood (1976) 2.29
Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol (2002) 2.28
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia (2009) 2.25
T-cell depletion of HLA-identical transplants in leukemia. Blood (1991) 2.25
Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst (1993) 2.21
Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs. Proc Natl Acad Sci U S A (1993) 2.12
Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood (1993) 2.12
Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med (1980) 2.11
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol (1993) 2.11
Problems of early infancy, formula changes, and mothers' beliefs about their infants. J Pediatr (1985) 2.09
Is there a T-cell form of chronic lymphocytic leukemia? Leukemia (1992) 2.08
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone Marrow Transplant (2002) 2.06
Ecology of Candida albicans gut colonization: inhibition of Candida adhesion, colonization, and dissemination from the gastrointestinal tract by bacterial antagonism. Infect Immun (1985) 2.03
Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. J Clin Oncol (2001) 2.01
Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. J Clin Oncol (1993) 2.00
High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med (1987) 1.98
What's new in blood progenitor cell autotransplants? Bone Marrow Transplant (1994) 1.98
Polymorphonuclear leukocytes in antibody-dependent cellular cytotoxicity. J Immunol (1975) 1.98
Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood (1990) 1.98
Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer (1995) 1.95
Differential Giemsa staining of sister chromatids and the study of chromatid exchanges without autoradiography. Chromosoma (1974) 1.94
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol (1991) 1.94
New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol (2000) 1.92
Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemias with the t(6;11) chromosome translocation. Cancer Res (1993) 1.89
Activation of human monocytes by streptococcal rhamnose glucose polymers is mediated by CD14 antigen, and mannan binding protein inhibits TNF-alpha release. J Immunol (1995) 1.89
Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med (1999) 1.88
Clinical evaluation of a self-rating scale for depressive disorder in childhood (Depression Self-Rating Scale). J Child Psychol Psychiatry (1987) 1.88
A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood (1979) 1.83
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant (2011) 1.82